A study conducted by Lynch et al. reported underutilization of guideline recommended PGx testing (e.g., EGFR testing in lung cancer) and substantial differences in the likelihood of getting tested based on the patient’s race as well as other demographic factors, including socioeconomic status and zip code [58]. The gene discussed is EGFR; the disease is lung cancer.